US supply agreement for additional AZD7442 doses
16 March 2021 07:00 GMT AstraZeneca to supply the US with up to half a million additionaldoses of the potential COVID-19 antibody treatment AZD7442 Agreement builds on an earlier announcement that includedsupport for the clinical development and supply of the treatment AstraZeneca has modified an existing agreement with the US Government to supply up to 500,000 additional doses of AZD7442, a long-acting antibody (LAAB) combination which is in late-stage development for the prevention and treatment of COVID-19. Today's agreement with the Department of Health and